Date: 2013-01-07
Type of information: Licensing agreement
Compound: intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR)
Company: Adaptimmune (UK) Life Technologies (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: Adaptimmune has secured an exclusive commercial license from Life Technologies Corporation for its intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR). (Life’s Dynabeads® CD3/CD28 CTS™ are the only GMP-grade reagents commercially available for use in clinical trials practicing these patented methods for the rapid expansion of autologous T cells in T cell therapy). The license agreements give Adaptimmune exclusive commercial rights to use Life’s beads and the processes for transduced TCRs used in T cell therapy. It does not affect the use of Life’s beads in other fields or for non-profit, non-commercial, or academic use.
Adaptimmune’s technology is based on enhancing the power of the T cell receptor on killer T cells. This involves taking the patient’s own T cells, genetically modifying them to present the selected TCR and then re-infusing the T cells into the patient. A critical step in this process is the stimulation and expansion of the T cells prior to re-infusion. Since Life Technologies’ beads are the only GMP-grade reagents commercially available for this patented process, this deal means that Adaptimmune has secured exclusive commercial access to the technology and the underlying manufacturing processes needed for obtaining regulatory approval of expansion of T cells carrying TCRs.
Financial terms: Financial terms of the licensing deal are not disclosed.
Latest news:
